Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
ARWR
Valuation N/A
ARROWHEAD PHARMACEUTICALS, INC.
Price$60.74
Model IV—
P/IV—
Market implies +27.9%/yr
ASBP
Valuation N/A
Aspire Biopharma Holdings, Inc.
Price$8.30
Model IV—
P/IV—
Market implies +116.2%/yr
ASBPW
Deeply overvalued
Aspire Biopharma Holdings, Inc.
Price$0.01
Model IV$0.01
P/IV2.64
Premium +77%
Return to IV: -43.6%
Market implies +0.0%/yr
vs model +15.0% · below model
ASMB
Deeply undervalued
ASSEMBLY BIOSCIENCES, INC.
Price$22.82
Model IV$40.07
P/IV0.57
Discount 43%
Return to IV: +75.6%
Market implies -9.4%/yr
vs model +50.0% · below model
ASND
Deeply overvalued
Ascendis Pharma A/S
Price$222.69
Model IV$133.67
P/IV1.78
Premium +67%
Return to IV: -40.0%
Market implies +4.4%/yr
vs model +50.0% · below model
ASRT
Valuation N/A
ASRT
Price$23.50
Model IV—
P/IV—
Limited data — see page
ATAI
Valuation N/A
ATAI
Price$7.35
Model IV—
P/IV—
Limited data — see page
ATHE
Valuation N/A
ALTERITY THERAPEUTICS LTD
Price$3.07
Model IV—
P/IV—
Limited data — see page
ATNM
Valuation N/A
Actinium Pharmaceuticals, Inc.
Price$1.08
Model IV—
P/IV—
Market implies +82.5%/yr
ATOS
Valuation N/A
ATOSSA THERAPEUTICS, INC.
Price$2.42
Model IV—
P/IV—
Limited data — see page
AUPH
Undervalued
Aurinia Pharmaceuticals Inc.
Price$16.22
Model IV$20.64
P/IV0.77
Discount 21%
Return to IV: +27.3%
Market implies +9.3%/yr
vs model +16.3% · below model
AVBP
Valuation N/A
ArriVent BioPharma, Inc.
Price$16.71
Model IV—
P/IV—
Limited data — see page
AVIR
Valuation N/A
Atea Pharmaceuticals, Inc.
Price$5.16
Model IV—
P/IV—
Market implies -0.3%/yr
AVLN
Valuation N/A
Avalyn Pharma Inc.
Price$25.72
Model IV—
P/IV—
Limited data — see page
AVTX
Valuation N/A
Avalo Therapeutics, Inc.
Price$13.43
Model IV—
P/IV—
Market implies +125.6%/yr
AXSM
Valuation N/A
Axsome Therapeutics, Inc.
Price$170.08
Model IV—
P/IV—
Market implies +20.1%/yr
AYTU
Overvalued
AYTU BIOPHARMA, INC
Price$2.05
Model IV$1.66
P/IV1.35
Premium +24%
Return to IV: -19.1%
Market implies +1.8%/yr
vs model +3.4% · in line
AZN
Deeply overvalued
ASTRAZENECA PLC
Price$158.78
Model IV$107.14
P/IV1.55
Premium +48%
Return to IV: -32.5%
Market implies +0.8%/yr
vs model +11.9% · below model
AZTR
Valuation N/A
Azitra, Inc.
Price$0.13
Model IV—
P/IV—
Market implies +57.2%/yr
BBIO
Deeply overvalued
BridgeBio Pharma, Inc.
Price$65.04
Model IV$21.58
P/IV3.21
Premium +201%
Return to IV: -66.8%
Market implies +13.1%/yr
vs model +50.0% · below model
BBOT
Valuation N/A
BridgeBio Oncology Therapeutics, Inc.
Price$3.42
Model IV—
P/IV—
Limited data — see page
BCAX
Valuation N/A
Bicara Therapeutics Inc.
Price$17.26
Model IV—
P/IV—
Limited data — see page
BCTX
Valuation N/A
BriaCell Therapeutics Corp.
Price$3.92
Model IV—
P/IV—
Limited data — see page
BCTXL
Valuation N/A
BriaCell Therapeutics Corp.
Price$1.11
Model IV—
P/IV—
Limited data — see page
BCTXZ
Valuation N/A
BriaCell Therapeutics Corp.
Price$0.25
Model IV—
P/IV—
Limited data — see page
BCYC
Undervalued
BICYCLE THERAPEUTICS PLC
Price$3.81
Model IV$5.11
P/IV0.70
Discount 25%
Return to IV: +34.1%
Market implies -5.6%/yr
vs model +50.0% · below model
BDRX
Valuation N/A
Biodexa Pharmaceuticals Plc
Price$0.52
Model IV—
P/IV—
Market implies +150.0%/yr
BFRG
Valuation N/A
BullFrog AI Holdings, Inc.
Price$0.69
Model IV—
P/IV—
Market implies +59.4%/yr
BFRGW
Valuation N/A
BullFrog AI Holdings, Inc.
Price$0.12
Model IV—
P/IV—
Market implies +37.5%/yr
vs model +15.0% · above model
BFRI
Deeply undervalued
Biofrontera Inc.
Price$0.92
Model IV$2.78
P/IV0.37
Discount 67%
Return to IV: +202.0%
Market implies -22.7%/yr
vs model +14.7% · below model
BFRIW
Valuation N/A
Biofrontera Inc.
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr
BGM
Valuation N/A
BGM Group Ltd.
Price$9.96
Model IV—
P/IV—
Market implies +77.9%/yr
BHC
Deeply undervalued
Bausch Health Companies Inc.
Price$6.04
Model IV$48.73
P/IV0.12
Discount 88%
Return to IV: +706.8%
Market implies -23.9%/yr
vs model +8.5% · below model
BHST
Deeply undervalued
BIOHARVEST SCIENCES INC.
Price$1.50
Model IV$5.36
P/IV0.28
Discount 72%
Return to IV: +258.7%
Market implies -24.2%/yr
vs model +50.0% · below model
BHVN
Valuation N/A
Biohaven Ltd.
Price$11.93
Model IV—
P/IV—
Limited data — see page
BIOA
Valuation N/A
BioAge Labs, Inc.
Price$6.21
Model IV—
P/IV—
Market implies +43.3%/yr
BIVI
Valuation N/A
BIOVIE INC.
Price$1.28
Model IV—
P/IV—
Limited data — see page
BIVIW
Valuation N/A
BIOVIE INC.
Price$0.27
Model IV—
P/IV—
Limited data — see page
BLRX
Valuation N/A
BioLineRx Ltd.
Price$2.21
Model IV—
P/IV—
Market implies +34.7%/yr
vs model +15.0% · above model
BLTE
Valuation N/A
BELITE BIO, INC
Price$152.52
Model IV—
P/IV—
Limited data — see page
BMEA
Valuation N/A
Biomea Fusion, Inc.
Price$1.37
Model IV—
P/IV—
Limited data — see page
BMRA
Valuation N/A
BIOMERICA INC
Price$1.89
Model IV—
P/IV—
Market implies +23.8%/yr
vs model +2.0% · above model
BMRN
Deeply undervalued
BIOMARIN PHARMACEUTICAL INC
Price$54.89
Model IV$82.26
P/IV0.70
Discount 33%
Return to IV: +49.9%
Market implies +3.8%/yr
vs model +11.5% · below model
BMY
Deeply undervalued
BRISTOL MYERS SQUIBB CO
Price$59.58
Model IV$142.13
P/IV0.45
Discount 58%
Return to IV: +138.6%
Market implies -5.3%/yr
vs model +7.3% · below model
BNTC
Valuation N/A
Benitec Biopharma Inc.
Price$8.75
Model IV—
P/IV—
Market implies +139.1%/yr
BOLD
Valuation N/A
Boundless Bio, Inc.
Price$2.58
Model IV—
P/IV—
Limited data — see page
BOLT
Deeply undervalued
Bolt Biotherapeutics, Inc.
Price$3.65
Model IV$14.49
P/IV0.26
Discount 75%
Return to IV: +297.0%
Market implies -26.4%/yr
vs model +50.0% · below model
BON
Deeply undervalued
Bon Natural Life Ltd
Price$1.17
Model IV$1.79
P/IV0.68
Discount 35%
Return to IV: +53.6%
Market implies -9.2%/yr
vs model +2.0% · below model
BRNS
Valuation N/A
Barinthus Biotherapeutics plc.
Price$0.74
Model IV—
P/IV—
Market implies +5.9%/yr
BTAI
Valuation N/A
BTAI
Price$0.05
Model IV—
P/IV—
Limited data — see page
BTMD
Deeply undervalued
biote Corp.
Price$1.17
Model IV$7.34
P/IV0.18
Discount 84%
Return to IV: +527.6%
Market implies -27.3%/yr
vs model +9.5% · below model
BYSI
Valuation N/A
BeyondSpring Inc.
Price$0.61
Model IV—
P/IV—
Market implies +34.0%/yr
CALC
Valuation N/A
CalciMedica, Inc.
Price$1.30
Model IV—
P/IV—
Limited data — see page
CAMP
Valuation N/A
Camp4 Therapeutics Corp
Price$3.70
Model IV—
P/IV—
Market implies +25.1%/yr
CANF
Valuation N/A
Can-Fite BioPharma Ltd.
Price$2.00
Model IV—
P/IV—
Market implies +27.9%/yr
CAPR
Valuation N/A
CAPRICOR THERAPEUTICS, INC.
Price$8.01
Model IV—
P/IV—
Market implies +32.7%/yr
CATX
Valuation N/A
Perspective Therapeutics, Inc.
Price$2.71
Model IV—
P/IV—
Market implies +65.1%/yr
CBIO
Valuation N/A
CRESCENT BIOPHARMA, INC.
Price$14.12
Model IV—
P/IV—
Market implies +21.7%/yr
CDIO
Valuation N/A
Cardio Diagnostics Holdings, Inc.
Price$1.86
Model IV—
P/IV—
Market implies +78.9%/yr
vs model +50.0% · above model
CDIOW
Deeply undervalued
Cardio Diagnostics Holdings, Inc.
Price$0.01
Model IV$0.03
P/IV0.33
Discount 69%
Return to IV: +226.1%
Market implies -25.0%/yr
vs model +50.0% · below model